Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Varlitinib (Primary) ; Capecitabine; Cisplatin; Fluorouracil
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors ASLAN Pharmaceuticals
- 06 Jun 2017 Initial results assessing the (n=27) safety and efficacy of varlitinib in combination with cisplatin and 5-fluorouracil or cisplatin and capecitabine in patients with metastatic solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 26 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 26 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History